Health
Triggering tumor antiviral immune response in triple negative breast cancer – EurekAlert
Researchers at Baylor College of Medicine have discovered how therapeutics targeting RNA splicing can activate antiviral immune pathways in triple negative breast…
HOUSTON – (Jan. 14, 2021) – Researchers at Baylor College of Medicine have discovered how therapeutics targeting RNA splicing can activate antiviral immune pathways in triple negative breast cancers (TNBC) to trigger tumor cell death and signal the body’s immune response. A new study published in Cell shows that endogenous mis-spliced RNA in tumor cells mimics an RNA virus, leading tumor cells to self-destruct as if fighting an infection. Researchers suggest this mechanism could open new avenues…
-
Noosa News18 hours agoBrisbane vs Collingwood live blog: Richmond selects Noah Balta as unbeaten Lions prepare for Magpies test
-
General24 hours agoMinecraft mayhem: ‘Chicken jockey’ chaos reaches Australian cinemas
-
General18 hours agoCanberra man named as doctor accused of rape after suppression order lifted
-
Noosa News20 hours agoAustralians tell ABC’s Your Say how they saw the second leaders debate